Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Publication bias in pharmacogenetics of statin-associated muscle symptoms: A meta-epidemiological study.

Atherosclerosis - 1 Jan 2025

Gougeon A, Aribi I, Guernouche S, Lega J C, Wright J M, Verstuyft C, Lajoinie A, Gueyffier F, Grenet G

Abstract excerpt

BACKGROUND AND AIMS: Statin-associated muscle symptoms (SAMS) are a major cause of treatment discontinuation. Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend dose adjustment for statin treatment according to known SLCO1B1 genotype to reduce SAMS. We hypothesized that the association between SLCO1B1 genotype and SAMS is misestimated because of publication bias. METHODS: We searched published...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bayes Theorem
Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver-Specific Organic Anion Transporter 1

Share to Muscular Diseases

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Publication Bias

Source

Identifiers

PMID: 39488449
DOI: 10.1016/j.atherosclerosis.2024.118624

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Publication bias in pharmacogenetics of statin-associated muscle symptoms: A meta-epidemiological study.PMID 39488449Read ↗

Publication bias in pharmacogenetics of statin-associated muscle symptoms, an umbrella review with a meta-epidemiological studySemantic proximity Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies.Semantic proximity Read ↗

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.Semantic proximity Read ↗

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Semantic proximity Read ↗

SLCO1B1 Polymorphisms and Statin-Induced MyopathySemantic proximity Read ↗

Pharmacogenetics of Statin-Induced MyotoxicitySemantic proximity Read ↗

Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.Semantic proximity Read ↗

Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.Semantic proximity Read ↗

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.Semantic proximity Read ↗

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.Semantic proximity Read ↗

Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.